ETF Evaluator:
Global X Genomics & Biotechnology ETF (GNOM)
Follow This ETF
(as of Jul 31)
Best Performing in Health Over the Last Year
| 177.8% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 114.6% | ALPS Medical Breakthroughs ETF (SBIO) |
| 91.7% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 83.9% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 79.5% | iShares Neuroscience and Healthcare ETF (IBRN) |
Risk
Index
Risk
Index
ETF Details
Global X Genomics & Biotechnology ETF Overview
Global X Genomics & Biotechnology ETF (GNOM) is a passively managed Sector Equity Health exchange-traded fund (ETF). Global X Funds launched the ETF in 2019.
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index").
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
About Global X Genomics & Biotechnology ETF (GNOM)
There are 2 members of the management team with an average tenure of 7.24 years: Nam To (2019) and Wayne Xie (2019). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: MSCI ACWI NR USD index with a weighting of 100% and Solactive Genomics NR USD index with a weighting of 100%. Global X Genomics & Biotechnology ETF has 51 securities in its portfolio. The top 10 holdings constitute 43.8% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Global X Genomics & Biotechnology ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Global X Genomics & Biotechnology ETF has 7.9% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 92.0% There is 7.9% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Global X Genomics & Biotechnology ETF has 0.1% of the portfolio in cash.
Assets Under Management
The fund has $76 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
GNOM Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Global X Genomics & Biotechnology ETF expense ratio is average compared to funds in the Health category. Global X Genomics & Biotechnology ETF has an expense ratio of 0.50%, which is 4% lower than its category average, making the fund expense ratio grade a C. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Global X Genomics & Biotechnology ETF has a portfolio turnover rate of 34%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 40% for the Health category.
Recently, in the month of June 2026, Global X Genomics & Biotechnology ETF returned 14.3%, which earned it a grade of A, as the Health category had an average return of 8.7%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Global X Genomics & Biotechnology ETF has a trailing yield of 1.15%, which is above the 1.12% category average.
The fund normally distributes its income semi-annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Global X Genomics & Biotechnology ETF Grades
Year to date, the ETF has returned 24.6%, 14.4 percentage points better than the category, which translates into a grade of A. The fund has returned 70.6% over the past year (grade of A), 5.9% over the past three years (grade of D) and -10.4% per year over the past five years (grade of F).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Global X Genomics & Biotechnology ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
GNOM Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| GNOM Return (NAV) | 14.3% | 29.7% | 70.6% | 5.9% | -10.4% | na |
| GNOM Return (Price) | 14.5% | 30.1% | 70.9% | 6.0% | -10.3% | na |
| NAV +/- Price Return | -0.163% | -0.390% | -0.293% | -0.044% | -0.030% | na |
| Health Avg | 8.7% | 13.9% | 37.6% | 10.6% | 1.5% | 9.5% |
| GNOM Grade (NAV) | A | A | A | D | F | na |
| +/- Category (NAV) | 5.7% | 15.7% | 33.0% | -4.7% | -11.9% | na |
| GNOM Tax-Cost Ratio | na | na | 0.6% | 0.2% | 0.1% | na |
GNOM Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| GNOM Return (NAV) | 24.6% | 19.0% | -16.2% | -8.6% | -36.1% | -16.0% | 51.6% | na | na | na | na |
| GNOM Return (Price) | 25.2% | 18.7% | -16.0% | -8.6% | -36.3% | -15.9% | 51.5% | na | na | na | na |
| NAV +/- Price Ret | 0.024% | -0.018% | -0.011% | 0.003% | 0.005% | -0.004% | -0.002% | na | na | na | na |
| Health Avg | 10.1% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| GNOM Grade (NAV) | A | C | F | F | F | F | A | na | na | na | na |
| +/- Category | 14.4% | -2.8% | -16.2% | -10.8% | -19.8% | -20.3% | 21.1% | na | na | na | na |
| Risk Measures | |
| Beta: | 1.60 |
| R-Squared: | 45% |
| Standard Deviation: | 29.9% |
| Category Risk Index: | 1.50 |
| Category Risk Rating: | High |
| Total Risk Index: | 2.46 |
| Total Risk Rating: | High |
| Portfolio Characteristics | |
| Yield: | 1.2% |
| Total Assets: | $ 77 Mil |
| Share Class Assets: | $ 77 Mil |
| Turnover: | 34.0% |
| Expense Ratio: | 0.50% |
| Index Fund: | Yes |
| Index Tracked: | MSCI ACWI NR USD |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | |
| Income Distribution Frequency: | Semi-Annually |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 7.2 years | |||
| Average Tenure: 7.2 years | |||
| Managers (Year): To Nam (2019), Xie Wayne (2019) | |||
Portfolio Composition (as of 6/30/26)
| # of Holdings: | 51 |
| % in Top 10 Holdings: | 43.8% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 7.9% |
Portfolio Allocation |
|
| Domestic Stock: | 92.0% |
| Foreign Stock: | 7.9% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Global X Funds |
| Phone Number: | 888-493-8631 |
| Website: | www.globalxfunds.com |
| Inception Date: | April 5, 2019 |
Expenses and Fees
| Expense Ratio (%): | 0.50% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.52% |
